Importance of antibody isotypes in antitumor immunity by monocytes and complement using human‐immune tumor models
Open Access
- 2 February 2021
- journal article
- research article
- Published by Wiley in European Journal of Immunology
- Vol. 51 (5) , 1218-1233
Abstract
Monoclonal antibodies (mAbs) have revolutionized clinical medicine, especially in the field of cancer immunotherapy. The challenge now is to improve the response rates, as immunotherapy still fails for many patients. Strategies to enhance tumor cell death is a fundamental aim, but relevant model systems for human tumor immunology are lacking. Herein, we have developed a preclinical human immune – three‐dimensional (3D) tumor model (spheroids) to map the efficiency of tumor‐specific isotypes for improved tumor cell killing. Different anti‐CD20 Rituximab (RTX) isotypes alone or in combination, were evaluated for mediating complement‐dependent cytotoxicity and antibody‐dependent phagocytosis by human monocytic cells in 3D spheroids, in parallel with monolayer cultures, of human CD20+ B‐cell lymphomas. We demonstrate that the IgG3 variant of RTX has the greatest tumoricidal effect over other isotypes, and when combined with apoptosis‐inducing RTX‐IgG2 isotype the therapeutic effect can be substantially enhanced. The results show further that the treatment outcome by RTX isotypes is influenced by tumor morphology and expression of the complement inhibitor CD59. Hence, the human immune‐3D tumor model is a clinical relevant and attractive ex vivo system to predict mAbs for best efficacy in cancer immunotherapy.Keywords
All Related Versions
Funding Information
- Vetenskapsrådet
This publication has 43 references indexed in Scilit:
- Rituximab for the treatment of rheumatoid arthritis: an updateDrug Design, Development and Therapy, 2013
- Spheroid culture as a tool for creating 3D complex tissuesTrends in Biotechnology, 2013
- Human CD59 Inhibitor Sensitizes Rituximab-Resistant Lymphoma Cells to Complement-Mediated CytolysisCancer Research, 2011
- Therapeutic antibodies: past, present and futureNature Reviews Immunology, 2010
- Therapeutic antibodies: successes, limitations and hopes for the futureBritish Journal of Pharmacology, 2009
- Optimization of antibody binding to FcγRIIa enhances macrophage phagocytosis of tumor cellsMolecular Cancer Therapeutics, 2008
- Isotype selection in antibody engineeringNature Biotechnology, 2007
- Rituximab-CHOP Versus CHOP Alone or With Maintenance Rituximab in Older Patients With Diffuse Large B-Cell LymphomaJournal of Clinical Oncology, 2006
- Two Immunoglobulin G Fragment C Receptor Polymorphisms Independently Predict Response to Rituximab in Patients With Follicular LymphomaJournal of Clinical Oncology, 2003
- Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa geneBlood, 2002